Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT was delisted on the 2nd of December, 2024.
24 hedge funds and large institutions have $4.05M invested in Oncternal Therapeutics, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 20 closing their positions.
0.88% more ownership
Funds ownership: 14.32% → 15.2% (+0.88%)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
11% less capital invested
Capital invested by funds: $4.53M → $4.05M (-$478K)
37% less funds holding
Funds holding: 38 → 24 (-14)
65% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
QPW
Quantum Private Wealth
Tampa,
Florida
|
+$244K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$228K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$212K |
| 4 |
BJL
Brighton Jones LLC
Seattle,
Washington
|
+$149K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$89.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PPW
Pasadena Private Wealth
Pasadena,
California
|
-$268K |
| 2 |
LPL Financial
San Diego,
California
|
-$91.9K |
| 3 |
State Street
Boston,
Massachusetts
|
-$86.5K |
| 4 |
IC
IEQ Capital
Foster City,
California
|
-$77.4K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$45.4K |
ONCT Hedge Fund Activity: Q1 2024 in Review
24 of the 6,959 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q1 2024, worth a combined $4.05M — down 11% from $4.53M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of ONCT and 7 opened new positions — a net loss of 13 holders — while 5 trimmed existing stakes and 5 added.
The largest buyer was Quantum Private Wealth, opening a new position worth an estimated $244K. The largest seller was Pasadena Private Wealth, exiting entirely with an estimated $268K sold.
- 24 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q1 2024, down from 38 in Q4 2023.
- Funds reported $4.05M of Oncternal Therapeutics, Inc. Common Stock stock for Q1 2024, down 11% quarter-over-quarter.
- 7 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q1 2024 and 20 closed out, a net change of -13 holders.
- The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q1 2024 was Quantum Private Wealth, an estimated $244K added.
- The largest Oncternal Therapeutics, Inc. Common Stock seller in Q1 2024 was Pasadena Private Wealth, an estimated $268K sold.
Based on aggregated 13F filings for Q1 2024.